Quote from a clinical trial report (JGOG3022 trial):
Patients who were scheduled to receive bevacizumab concomitantly with platinum-based combination chemotherapy after PDS or IDS were included in the observation cohort of this study before enrollment.
This observation cohort is not mentioned anywhere else in the document. What is its purpose?
Higher in the text, there's a mention of PDS/IDS in the inclusion criteria paragraph:
(3) patients in whom the period from primary debulking surgery (PDS) or interval debulking surgery (IDS) to the initiation of bevacizumab was at least 28 days.
Does it mean that the "observation cohort" was meant for keeping patients under observation until the required perios of 28 days has elapsed, and then to decide whether they are fit to be enrolled in the trial and given additional bevacizumab with their chemo treatment?